Tolvaptan in portal hypertension: real life experience.

Marta Tejedor,Agustín Delgado,Rosa Melero,Víctor Fernández-Alonso,Magdalena Salcedo, Patrocinio Rodríguez-Benítez

Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva（2022）

引用 0|浏览1

暂无评分

摘要

Tolvaptan (TVP) is a selective antagonist of vasopressin receptors, approved for the treatment of hyponatremia in SIADH, congestive heart failure (CHF) and cirrhosis. We retrospectively reviewed all cases where TVP was used in a tertiary hospital (January 2012- January 2017). Our aim was to study the use of TVP in real life practice in patients with portal hypertension (PHT) (past history of non-malignant ascites or variceal bleed).

查看译文

关键词

portal hypertension

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要